# Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550-or/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Roy Fleischmann,Maurizio Cutolo,Mark C. Genovese,Eun Bong Lee,Keith S. Kanik,Seth Sadis,Carol A. Connell,David Gruben,Sriram Krishnaswami,Gene V. Wallenstein,Bethanie Wilkinson,Samuel H. Zwillich |
| Citations | 379 |
| DOI | 10.1002/art.33383 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1990105300 |
| PMID | 21952978 |
| Type | article |
| Year | 2011 |

## Paper authors

- [David Gruben](https://scholariq.org/researchers/david-gruben/)

## Paper primary topic

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Paper topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.